New drug aims to unload the heart in lung hypertension
NCT ID NCT06658522
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests whether the drug sotatercept can improve right heart function in people with pulmonary arterial hypertension (PAH). PAH causes high blood pressure in the lungs, straining the right side of the heart. Sotatercept targets the underlying blood vessel changes, not just widening vessels. Twenty adults will receive injections every three weeks for 24 weeks, and doctors will measure heart function with imaging and catheterization. The goal is to see if the drug makes the heart work more efficiently.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sotatercept (a drug injected under the skin)
What this could lead to
If it works, this could show that sotatercept improves heart efficiency and delays right heart failure in people with pulmonary arterial hypertension.
What could go wrong
This is a small, early-phase study with only 20 participants and no placebo group, so results may not apply broadly. The drug may not improve heart function as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amsterdam UMC, location VUMC
RECRUITINGAmsterdam, North Holland, 1081HV, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact